Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Adobe Systems Inc. (NASDAQ: ADBE) shares increased 0.63 percent to close at $46.06 a share Monday. The stock traded between $46.01 and $46.61 on volume of 2.59 million shares traded. Analysts at Pacific Crest have recently upgraded the company’s rating to "outperform" from "sector perform". Shares of Adobe Systems have gained approximately 22.0 percent year-to-date.
Find out more about Adobe Systems including full access to the free equity report at:
www.RDInvesting.com/ADBE
Alliant Techsystems Inc. (NYSE: ATK) shares increased 0.94 percent to close at $101.57 a share Monday. The stock traded between $101.27 and $103.77 on volume of 429,941 shares traded. Analysts at Drexel Hamilton have recently upgraded the company’s rating to "buy" and currently have a $110.00 price target on the stock. Shares of Alliant Techsystems have gained approximately 64.0 percent year-to-date.
Find out more about Alliant Techsystems including full access to the free equity report at:
www.RDInvesting.com/ATK
Hasbro, Inc. (NASDAQ: HAS) shares gained 0.61 percent to close at $46.39 a share Monday. The stock traded between $46.29 and $47.61 on volume of 1.53 million shares traded. Analysts at Citigroup have recently upgraded the company’s rating to "buy" and have also raised its price target to $53.00. Shares of Hasbro have gained approximately 29.0 percent year-to-date.
Find out more about Hasbro including full access to the free equity report at:
www.RDInvesting.com/HAS
ImmunoGen, Inc. (NASDAQ: IMGN) shares increased 1.98 percent to close at $16.48 a share Monday. The stock traded between $16.10 and $16.82 on volume of 837,042 shares traded. Analysts at Roth Capital have recently initiated coverage on the company with a "buy" rating and a price target of $19.00. Shares of ImmunoGen have gained approximately 29.0 percent year-to-date.
Find out more about ImmunoGen including full access to the free equity report at:
www.RDInvesting.com/IMGN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]